Stavinor

Atorvastatin Ca

Adjunct to diet for the reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, & triglycerides in patients w/ primary hypercholesterolemia, combined (mixed) hyperlipidemia, & heterozygous & homozygous familial hypercholesterolemia, reduce the risk of fatal CHD & non fatal MI, stroke, revascularization procedures & angina pectoris. In hypertensive patients (≥40 yr) & dyslipidemia w/ at least 3 risk factors for future CV events eg, LVH, ECG abnormalities, NIDDM. Ped patients (10-17 yr): Adjunct to diet to reduce total-C, LDL-C, & apo-B levels in boys & postmenarchal girls, 10-17 yr, w/ heterozygous familial hypercholesterolemia. LDL-C remains ≥190 mg/dL or ≥160 mg/dL & there is a positive family history of premature CV disease or ≥2 other CVD risk factors are present in the ped patients.

10-80 mg once daily.

May be taken with or without food.

Active liver disease or unexplained persistent elevations of serum transaminase >3 times the upper limit of normal.

Monitor for creatinine phosphokinase & transaminase elevations. Avoid alcohol consumption. Pregnancy & lactation.

GI disturbances, headache, myalgia, asthenia, insomnia, angioneurotic edema, muscle cramps, myositis, myopathy, cholestatic jaundice, peripheral neuropathy, pruritus.

Risk of myopathy increased w/ concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, niacin, or azole antifungals. Decreased atorvastatin plasma conc w/ oral antacid susp containing Mg & Al hydroxides & colestipol. Increases steady-state plasma digoxin conc. Increased atorvastatin plasma conc w/ erythromycin. Increases AUC values for norethindrone & ethinylestradiol.

Dyslipidaemic Agents

C10AA05 - atorvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.

G